EUVIMEDEUVIMED entdecken
Crossref

ENO1 lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer

Tian Zeng, Qianqian Wang, Lei Li, Xiongjin Tan, Jing He, Yan Liu, Xiaodong Wang, Rongfang He, Gouping Ding, Xinyi Zeng, Xing Tang, Xun Chen und 2 weitere

Drug Resistance Updates · 2026-07 · 87 · 101413

DOI: 10.1016/j.drup.2026.101413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-07. Verfasst von Tian Zeng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007,…. Hauptthemen laut MEDLINE: Phosphopyruvate Hydratase, Drug Resistance, Neoplasm, Bevacizumab, Ovarian Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bevacizumab, a monoclonal antibody targeting Vascular Endothelial Growth Factor (VEGF), is a cornerstone therapy for ovarian cancer (OC). However, acquired resistance to bevacizumab remains a major clinical challenge. Metabolic reprogramming in the tumor microenvironment, particularly lactate-driven lactylation modifications, has been implicated in drug resistance; however, the specific mechanisms underlying bevacizumab resistance are poorly understood. This study identifies Enolase 1 (ENO1) lactylation as a key driver of drug resistance through the integration of lactylation proteomics in patient samples, functional validation in cell lines and in vivo models Patient-Derived Xenograft (PDX), zebrafish, and chicken Chorioallantoic Membrane (CAM)). We observed significantly elevated pan-lactylation in bevacizumab-resistant OC tissues, correlating with enhanced angiogenesis and poor prognosis. Mechanistically, alanyl-tRNA synthetase 1 (AARS1) mediated lactylation of ENO1 at lysine 71 (K71) augmented lactate synthesis and promoted histone lactylation marks (Lysine lactylation of histone H3 at lysine 9 (H3K9la) and Lysine Lactylation of Histone H3 at Lysine 14 (H3K14la)). This epigenetic reprogramming upregulated the transcription of the angiogenic factor Endothelial cell-specific molecule 1 (ESM1), establishing a positive feedback loop for ENO1 expression. Secreted ESM1 stabilized the transcription factor YY1 in endothelial cells by competitively inhibiting Smurf2-mediated ubiquitination, leading to YY1-dependent recruitment of E1A Binding Protein p300 (EP300) and Histone H3 Lysine 27 (H3K27) acetylation at the B-cell lymphoma 2-related protein A1 (BCL2A1) promoter. This cascade enhanced endothelial cell survival and angiogenesis, ultimately fostering resistance to bevacizumab. Our findings reveal a metabolic-epigenetic axis centered on ENO1 K71 lactylation that perpetuates resistance to bevacizumab, highlighting its potential as a therapeutic target to restore bevacizumab efficacy in OC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphopyruvate HydrataseDrug Resistance, NeoplasmBevacizumabOvarian NeoplasmsDNA-Binding ProteinsNeovascularization, PathologicTumor Suppressor ProteinsFemaleHumansMetabolic ReprogrammingAnimalsAngiogenesis InhibitorsZebrafishCell Line, TumorXenograft Model Antitumor AssaysHistonesAntineoplastic Agents, ImmunologicalGene Expression Regulation, NeoplasticChorioallantoic MembraneTumor MicroenvironmentChickens

Stichwörter der Autor:innen

AngiogenesisBevacizumab resistanceENO1Lactylation modification

Substanzen

Phosphopyruvate HydrataseBevacizumabENO1 protein, humanDNA-Binding ProteinsTumor Suppressor ProteinsAngiogenesis InhibitorsHistonesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007, China.
  • Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007, China; Department of Oncology, The Affiliated Zhuzhou Hospital of Xia…
  • Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007, China; Department of Pathology, The First Affiliated Hospital, Hengya…
  • 922 Hospital of PLA, Hengyang, Hunan 410011, China.
  • Department of Oncology, The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007, China.
  • Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Zeng, T., Wang, Q., Li, L., Tan, X., He, J., Liu, Y., Wang, X., He, R., Ding, G., Zeng, X., Tang, X., Chen, X., Huang, H., & Li, Y. (2026). ENO1 lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer. Drug Resistance Updates, 87, 101413. https://doi.org/10.1016/j.drup.2026.101413

Vancouver

Zeng T, Wang Q, Li L, Tan X, He J, Liu Y, et al. ENO1 lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer. Drug Resistance Updates. 2026;87:101413. doi:10.1016/j.drup.2026.101413

BibTeX
@article{Zeng2026,
  author = {Zeng, Tian and Wang, Qianqian and Li, Lei and Tan, Xiongjin and He, Jing and Liu, Yan and Wang, Xiaodong and He, Rongfang and Ding, Gouping and Zeng, Xinyi and Tang, Xing and Chen, Xun and Huang, Hao and Li, Yukun},
  title = {ENO1 lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {87},
  pages = {101413},
  doi = {10.1016/j.drup.2026.101413}
}
Kostenlos starten →